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Natural killer cells (NK cells) are a subset of peripheral blood lymphocytes that mediate non-major
histocompatibility complex-restricted cytotoxicity of foreign target cells. The ‘‘gold standard’’ assay for NK cell
activity has been the chromium release assay. This method is not easily performed in the clinical laboratory
because of difficulties with disposal of radioactive and hazardous materials, short reagent half-lives, expense,
and difficulties with assay standardization. We describe a flow cytometric assay for the clinical measurement
of NK cell activity. This study compared the chromium release assay and the flow cytometric assay by using
clinically relevant specimens. There were no significant differences between the two assays in the measurement
of lytic activity for 17 peripheral blood specimens or in reproducibility in repeated samplings of healthy
individuals. We also established a normal range of values for NK activity in healthy adults and identified a
small cluster of individuals who have exceptionally high or low levels of NK activity. The flow cytometric assay
was validated by testing specimens from subjects expected to have abnormally low levels of NK activity
(pregnant women) and specimens from healthy individuals in whom the activity of NK cells was enhanced by
exposure to interleukin-2 or alpha interferon. Treatment with these agents was associated with a significant
increase in NK activity. These results confirm and extend those of others, showing that the flow cytometric
assay is a viable alternative to the chromium release assay for measuring NK cell activity.
Natural killer cells (NK cells) are a subset of non-B, non-T
peripheral blood lymphocytes that appear to play a crucial role
in the human innate immune response (9, 16, 30). They medi-
ate a cell contact-dependent cytolysis of target cells, including
those expressing foreign major histocompatibility complex
(MHC) molecules, virally infected cells, and tumor cells. NK
cells are unusual among lymphocytes in that their function is
not restricted by cells expressing self MHC molecules (MHC
restricted) (9, 16). NK cells compose up to 15% of peripheral
blood lymphocytes (24, 30) and are not dependent on the
thymus for development, as evidenced by their normal expres-
sion and function in patients with severe combined immuno-
deficiency (9, 16, 24). They are large granular lymphocytes
which by definition fail to express the T-cell receptor or surface
immunoglobulin (9, 24, 30). NK cells are hypothesized to ex-
press an antigen receptor capable of recognizing and binding
foreign cells, but the identification and characterization of this
putative receptor are incomplete (9, 16, 30). Recent work has
identified a number of cell surface proteins which may be
involved in recognizing self MHC molecules and protecting
autologous cells from cytolysis (16).
The function of NK cells is important for the clearance of
tumor cells, for the removal of immunoglobulin-bound anti-
gens, and for the control of viral infections (24, 27, 30). NK
function has been reported to be decreased in certain people,
including those with primary immunodeficiencies, those with
late-stage human immunodeficiency virus infections, and preg-
nant women (5, 6, 11, 14, 21, 30). As more is learned about NK
cells and their function, and more simplified and precise means
to quantitate their numbers and function become available,
their analysis may become of more routine practical use to
certain clinical specialties. A low level of NK cell activity may
be useful in predicting patient outcome as well (6, 10, 11, 31).
Thus, a suitable clinical assay for NK cell activity is necessary.
The standard method for the determination of NK activity is
the chromium release assay (51Cr assay) (4, 6, 24, 32). How-
ever, this assay is not a preferred method for use in the clinical
laboratory for a variety of reasons; e.g., it requires the use of
radioactive chromium, which is inherently expensive, and en-
tails concerns in handling and disposal. Also, because of the
short half-life of chromium, this reagent must be continuously
replaced. Lastly, interlaboratory variability in this and other
functional assays is also of potential concern, especially since
proficiency testing programs are not routinely in place for
these assays.
For these reasons, investigators have developed new flow
cytometry-based, nonradioactive methods for measuring NK
cell activity (4, 6, 23, 28). Flow cytometric assays avoid the
problems associated with the use of radioactivity and are rapid
and more amenable to standardization. We compared a flow
cytometric assay with the 51Cr assay by using peripheral blood
lymphocytes from healthy human control subjects and patients.
In addition, individuals with decreased levels of NK activity
were analyzed to validate the usefulness of the flow cytometric
assay as a clinical assay. The modified flow cytometric function
assay gave results similar to those of the 51Cr assay and was less
expensive and less time-consuming.
MATERIALS AND METHODS
Blood donors. Donors were selected from laboratory volunteers ranging from
20 to 55 years of age, including both males and females. These subjects were
determined by interview to be healthy, free of medication, and not pregnant.
Pregnant donors with a gestational age greater than 26 weeks and considered
healthy by the referring physician were selected. Informed consent was obtained
from all donors in accordance with the policies of the University of North
Carolina Internal Review Board.
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Reagents. K562 cells were purchased from American Type Culture Collection
(Rockville, Md.). 3,39-Dioctadecyloxacarbocyanine perchlorate (DiO) (Molecu-
lar Probes, Eugene, Oreg.), was dissolved in dimethyl sulfoxide (Sigma, St. Louis,
Mo.) to a concentration of 30 mM. Aliquots were frozen at 2208C and thawed
each day. RPMI media containing penicillin, streptomycin, and gentamicin with
and without phenol red were obtained from Gibco (Grand Island, N.Y.). Com-
plete medium (CM) consisted of RPMI medium supplemented with 10% fetal
bovine serum, 100-U/ml penicillin, 100-mg/ml streptomycin, and 50-mg/ml gen-
tamicin. Propidium iodide (PI) (Sigma) was dissolved in CM to obtain a working
solution of 10 mg/100 ml. Fetal bovine serum was obtained from HyClone
(Logan, Utah), and lymphocyte separation medium was obtained from Organon-
Teknika (Durham, N.C.). Alpha interferon (IFN-a) (Roferon) was obtained
from Roche (Nutley, N.J.), and recombinant interleukin-2 (IL-2) was purchased
from Boehringer Mannheim (Indianapolis, Ind.).
The antibodies for flow cytometric analysis, obtained from Becton Dickinson
Immunocytometry Systems (BDIS) (San Jose, Calif.), were as follows: CD2,
CD3, CD4, CD7, CD8, CD16, CD25, CD45, CD56, CD57, and CD69. These
antibodies were directly conjugated with fluorescein isothiocyanate, phyco-
erythrin, or peridinin chlorophyll protein and were used at concentrations rec-
ommended by the manufacturer.
Preparation of target cells. K562 cells were grown as stationary cultures in CM
and maintained at 378C in 5% CO2. For the 3 days prior to the assay, cells were
subcultured every 24 h to ensure that they were in log phase. K562 cells were
washed and resuspended at a concentration of 106 cells per ml in phosphate-
buffered saline (PBS). Prior to use in the assay, these cells were labeled by adding
10 ml of 30 mM DiO per ml of K562 cells, and the cells were incubated at 378C
in 5% CO2 for 20 min. They were washed twice in PBS and resuspended to a final
concentration of 106 cells per ml in CM without phenol red.
Effector cell preparation. Peripheral blood mononuclear cells (PBMCs) were
used in the 51Cr and flow cytometric assays and were separated from heparinized
blood by using lymphocyte separation medium as previously described (25). The
PBMCs were washed twice with unsupplemented RPMI medium and resus-
pended to a final concentration of 3.85 3 106 cells per ml in CM without phenol
red.
51Cr assay. K562 cells were grown and washed as described above and further
prepared as previously described (4). Briefly, 100 to 200 mCi of 51Cr was added,
and the cells were returned to the incubator for 1 h. The cells were washed twice
and resuspended to 5 3 104 cells per ml and kept in the incubator until needed.
PBMCs were used in effector-to-target (E/T) ratios of 50:1, 25:1, 12.5:1, and
6.25:1, except where indicated. These ratios were based on previously published
results (4) and were modified following optimizing titration experiments. Target
and effector cells were mixed in a 96-well plate which was then briefly centrifuged
and placed in a CO2 incubator for 4 h. An aliquot of 100 ml of supernatant was
removed, and the amount of radioactivity was measured with a gamma counter.
Each ratio was determined in triplicate. Percent cytotoxicity was calculated as
follows: percent cytotoxicity 5 [(experimental release 2 spontaneous release)/
(maximum release 2 spontaneous release)] 3 100.
NK flow cytometric assay. The method for the NK flow cytometric assay was
modified from and is a composite of two previously published methods for
measuring NK activity (4, 6). Target cells (10 ml) at the standard concentration
and 130 ml of PBMCs (effector cells) at 1:1 (neat), 1:2, 1:4, and 1:8 dilutions were
added to tubes (12 by 75 mm) to create E/T ratios within a range from 50:1 to
6.25:1. A total of 130 ml of PI was added, and the tubes were centrifuged for 30
s at 1,000 3 g to pellet the effector and target cells together in the presence of
the PI. These cell mixtures were incubated for 2 h at 378C in 5% CO2. Controls
consisted of target cells only plus PI and effector cells only plus PI and were set
up to detect spontaneous lysis and nonviable effector cells, respectively. After the
cells were incubated together, they were analyzed by flow cytometry. For poten-
tiation experiments, IL-2 (250 U/ml) and IFN-a (40 U/ml) were added to the
PBMCs and target cells, and the mixtures were incubated overnight at 378C in
5% CO2. Controls contained cells that had been incubated overnight in CM.
These cells were then used in the flow cytometric assay as described above. For
flow cytometric analysis, the samples were gently mixed and analyzed on a
FACScan flow cytometer (BDIS). The flow cytometer was operated in accor-
dance with the manufacturer’s recommendations after daily analysis of BDIS
Calibrite Autocomp beads and fine adjustments for optimization. The forward-
and side-scatter parameters were adjusted to accommodate the inclusion of both
target and effector cells within the acquisition gate. No cells were excluded from
the analysis, and 10,000 cells were counted. Data were collected by using the
Consort30 (BDIS) program and analyzed with Lysis software (BDIS). Data are
presented in Fig. 1 as a dot plot of FL1 (FITC fluorescence) versus FL2 (PI
fluorescence) with quadrant markers drawn to distinguish DiO-labeled cells and
cells which had incorporated PI. Percent lysis was calculated from the following
equation: percent lysis 5 [quadrant 2 events/(quadrant 2 1 quadrant 4 events)]
3 100. The same equation was used to calculate the percent spontaneous lysis for
a sample containing only target cells. The spontaneous lysis was subtracted from
the actual lysis for each sample.
Flow cytometric immunophenotyping. To determine the immunophenotype of
the activated NK cells, the cytokine-pretreated cells and control cells were
centrifuged following overnight incubation with the cytokines and were resus-
pended at 107 cells per ml in PBS. A total of 106 cells were incubated with the
appropriate fluorescently labeled monoclonal antibodies for 30 min on ice. The
cells were washed twice with PBS and were resuspended to 106 cells per ml in
PBS and analyzed by flow cytometry on the FACSort flow cytometer (BDIS) by
following the procedure described above.
Statistical analysis. Data are presented as means 6 standard errors of the
means at the indicated E/T ratios. Comparisons of the 51Cr and flow cytometric
assays, the reproducibility studies, and the effects of cytokine stimulation were all
performed by using the Wilcoxon signed-rank test. The paired t test was used for
comparisons of surface marker expression between control and cytokine-treated
PBMCs.
RESULTS
Comparison of 51Cr and flow cytometric NK assays. Seven-
teen peripheral blood specimens from eight healthy adult vol-
unteers were obtained, and the 51Cr and flow cytometric assays
were performed on each. The correlation (r 5 0.85) in percent
cytotoxicity between the two methods was high (Fig. 2A), and
the dose-response curves were similar (Fig. 2B). In addition,
there was no statistically significant difference between the two
methods (P . 0.05) when the data from each were converted
to lytic units (144 6 39 and 170 6 17 lytic units for the flow
cytometric and 51Cr assays, respectively).
Reproducibility of the flow cytometric method. The repro-
ducibility of the flow cytometric method for detecting NK
activity in human peripheral blood lymphocytes was deter-
mined by performing repeated analyses for the same individ-
uals over time. Six healthy adult individuals donated blood on
three separate occasions over a 1-month period, and PBMCs
were tested by the flow cytometric and 51Cr assays. There were
no significant differences (P . 0.05) in the mean percent cy-
totoxicity determined by either method between time periods
or between the methods at each time period (Fig. 3) when a
50:1 E/T ratio was used.
Range of NK activity for healthy adults. For the implemen-
tation of the flow cytometry assay in a clinical laboratory set-
ting, values for healthy individuals should be determined. To
establish a normal range, 87 PBMC specimens were obtained
from healthy adults, and the NK activity was determined by
flow cytometry for each. The mean percent cytotoxicity at the
50:1 E/T ratio was 41.4% 6 15.0%.
FIG. 1. Dual-parameter dot plot (FL1 [FITC fluorescence] and FL2 [PI
fluorescence]) of PBMCs (effector cells) and DiO-labeled target cells. Quadrant
1 contains nonviable effector cells, quadrant 2 contains viable target cells, quad-
rant 3 contains viable effector cells and viable target cells without any dye uptake,
and quadrant 4 contains viable target cells.
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NK activity in late pregnancy. To validate the flow cytomet-
ric assay for detecting low levels of NK activity, blood was
obtained from pregnant women and tested for NK activity.
Pregnant women, especially those in a late stage of gestation,
have been shown by others to have abnormally low NK activity
levels (5, 14, 15, 19, 24, 25). The mean NK activity (50:1 E/T
ratio) of the pregnant subjects (28.6% 6 14.2%) was signifi-
cantly lower (P, 0.05) than that of 22 healthy adult volunteers
who were assayed concurrently (mean NK activity, 41.7% 6
15.0%).
Augmentation of NK activity by cytokine addition. The va-
lidity of the flow method was also analyzed by determining
whether a change in NK activity to levels greater than typically
expected could be detected. Previous reports have suggested
that the cytokines IL-2 and IFN-a increase the activity of NK
cells against tumor cell targets (2, 3, 7–9, 18, 21, 24, 30). To test
this effect by the flow cytometric assay, PBMCs from healthy
individuals were treated with these cytokines, and the change
in NK activity compared with the activity of nontreated cells
was determined. Figure 4 shows that treatment with these
cytokines caused a significant increase (P , 0.05) in the lytic
activity of both IL-2- and IFN-a-treated cells.
Immunophenotyping of NK cells. Distinct patterns of sur-
face marker expression on NK subsets may be related to the
activation state of the cells. To determine if activated NK cells
express surface markers different from those expressed by rest-
ing NK cells, flow cytometry was used to immunophenotype
NK cells of low normal individuals (individuals who are con-
sidered low normal responders for NK activity) incubated with
and without IL-2 or IFN-a. Changes in activation marker ex-
pression (CD69 and CD25) were observed in the treated spec-
imens. Cells that had been incubated with the cytokines
showed a significant increase in NK activity. However, the
testing of eight individuals was unable to show any consistent
changes in NK phenotype which paralleled the changes ob-
served in NK activity (Table 1).
DISCUSSION
NK cells, a small subset of peripheral blood lymphocytes
that mediate non-MHC-restricted cytotoxicity of foreign target
cells, appear to play a crucial role in immunologic defense and
regulation (9, 24, 30). There has been an increasing interest by
clinicians in accurately measuring in vitro NK cell activity be-
cause of possible correlations between NK cell activity and
disease outcome or progression (6, 10, 11, 13, 31). It was our
intention to find a simple and reproducible method for deter-
mining NK cell activity that could be incorporated into the
evaluation of immune parameters in patients with immunode-
ficiencies and psychiatric disorders.
The ‘‘gold standard’’ assay for NK cell activity has been the
51Cr assay (4, 6, 24, 32). In this assay, target cells internalize
radioactive chromium which is subsequently released upon
cytolysis by NK cells. The amount of radioactivity released can
be measured with a gamma counter. However, many difficul-
ties with this assay prevent it from being routinely used in
FIG. 2. (A) Scatter plot demonstrating the correlation of percent cytotoxicity
values for 17 samples analyzed by the flow cytometric and 51Cr assays. Data
indicate percent cytotoxicity at all E/T ratios. (B) Dose-response curves (means
6 standard errors of the means) of the flow cytometric ({) and 51Cr (E) assays.
FIG. 3. Percent cytotoxicity (mean 6 standard error of the mean) for six
individuals analyzed by the flow cytometric (■) and 51Cr ( ) assays at three
different time points. Measurements 2 and 3 were obtained from 1 to 6 weeks
after measurement 1. Data are for the 50:1 E/T ratio for each method.
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clinical settings. It is difficult to standardize, expensive, time-
consuming, uses reagents with short half-lives, and requires
disposal of radioactive and hazardous materials. Therefore,
another method for measuring NK cell activity would be de-
sirable.
Although many methods for the detection of NK cell activity
have been reported, two reports have recently documented
flow cytometry-based methods for measuring NK cell activity
(4, 6). Our method utilized the incorporation of a green li-
pophilic fluorescent dye, DiO, into the membranes of target
cells grown in culture. This dye allows the easy discrimination
of target cells from effector cells with a flow cytometer. Addi-
tionally, dead cells are identified by the intercalation of PI into
the nuclear DNA (20). Since PI fluoresces in the orange-red
spectrum, the percentage of target cells that have been dam-
aged by the effector NK cells can be accurately determined by
dual-fluorescence analysis.
Our method utilizes components of previously published
work (4, 6). However, our method of analysis differs from that
published by Chang et al. (4) in the way the cells are evaluated
and the way the percent lysis is calculated. By setting a thresh-
old on forward scatter to exclude debris and a threshold on
fluorescence detector 1 to exclude effector cells, their method
included only the acquisition of target cells. We felt it would be
more appropriate to include all events in the analysis of NK
activity, rather than narrowing our analysis to include only
target cells. This may be especially important because as cells
become damaged, their scatter properties change and target
and effector populations may become less distinct (20). The
calculation of percent cytotoxicity performed by Chang et al.
also included dimly DiO-positive cells which fell in quadrant 1
of the dual-fluorescence dot plot. In our analysis, target cells
were defined as those retaining bright DiO staining (no quad-
rant 1 events). It was reasoned that NK cells may also show
weakened membrane integrity following incubation and that
the percent lysis of targets might be overestimated if cells
which were stained with PI but not with DiO were included
(quadrant 1). Likewise, the total target population (quadrants
2 and 4) was used as the denominator when determining the
percent lysis by NK cells. This analysis is similar to that used by
Hatam et al. (6), who performed similar experiments with
PKH-26 as the membrane-intercalating dye instead of DiO.
The choice of either PKH-26 or DiO is most likely influenced
the most by personal preference in terms of emission spectra,
since both dyes label cells quickly and efficiently and do not
leak appreciably within the time frame of the flow cytometric
assay (4, 6).
Our method was compared with the 51Cr assay in a clinical
setting to determine if the flow cytometric method would be a
suitable alternative for measuring NK activity. The flow cyto-
metric assay gave results comparable to those obtained by the
51Cr assay and was found to be faster and easier to perform
than that assay.
NK activity normally may be inconsistent within an individ-
ual because of the many possible immunological and endocrine
influences on NK cells (1, 3, 5, 13, 18, 21, 24, 30). Therefore,
minor changes in NK activity may be expected when repeatedly
testing healthy individuals. However, our data demonstrate
that the flow cytometric assay is as reproducible as the 51Cr
assay when used to assay individuals repeatedly over time. In
fact, the flow cytometric assay was less variable than the 51Cr
assay.
To validate the results generated in the flow cytometric assay
we tested PBMCs from individuals who were expected to have
low levels of NK activity and PBMCs from individuals who
were expected to have increased levels of NK activity. Previous
results (5, 14, 19, 24, 25) support the conclusion that women in
late pregnancy have reduced levels of NK activity. Therefore,
this group was used as a representative group of individuals
with low-level NK activity. The flow cytometric method showed
significantly lower levels of NK activity in this group compared
with healthy individuals, as would be expected. We also eval-
uated the validity of the assay by comparing levels of NK
activity for the same individuals before and after treatment
with cytokines reported to enhance NK activity in vitro (7, 8,
18, 21). This was done to determine the ability of the flow
cytometric assay to detect higher levels of NK activity than
might normally be expected. Using the flow cytometric assay,
we were able to show significantly increased NK activity in cells
treated with either IL-2 or IFN-a. These cytokines were also
added together to test for a synergistic effect, but the dual
stimulation was not significantly different from that produced
by IL-2 alone (data not shown). Thus, the observations that the
flow cytometric assay accurately identifies increases and de-
creases in NK activity support its use for clinical determina-
tions of NK activity.
FIG. 4. NK activities (means 6 standard errors of the means) of PBMCs
from six individuals pretreated with CM (none) or 250 U of IL-2 per ml or 40 U
of IFN-a per ml. p, P , 0.05 for cytokine pretreatment versus no pretreatment.
TABLE 1. Immunophenotypes of cytokine-treated cells
Surface antigen
% Positively staining cells witha:
No pretreatment IFN-a IL-2
CD2 79.1 78.1 78.0
CD3 71.5 69.8b 71.6
CD7 83.4 82.7 83.6
CD8 30.0 29.0b 28.1b
CD161/CD32 8.1 7.3b 7.0
CD19 8.0 7.8 8.3
CD25 14.6 17.5b 15.5
CD45 97.1 97.3 97.3
CD561/CD32 3.3 3.0 3.1
CD57 13.6 13.3 12.5
CD69 6.8 21.7b 21.3b
a Cells were pretreated with 40 U of IFN-a per ml or 250 U of IL-2 per ml.
b P , 0.05 for pretreated cells versus control cells not pretreated.
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To use the flow cytometric NK assay clinically, a range of
normal results should be established. By testing a large number
of healthy adults, it was determined that the majority of indi-
viduals were within 1 standard deviation of the mean of our
normal range for NK activity (data not shown). There are a few
individuals who were consistently outside 1 standard deviation.
These results suggest that there are low, normal, and high
responders for NK activity. These categories may be useful to
clinicians who are trying to compare patient results with results
for healthy controls. As more test results are collected, a more
precise definition of each of the three categories may be ob-
tained. Having a suitable and rapid flow cytometry-based assay
for the measurement of NK activity would be very advanta-
geous for the evaluation of patients with immunodeficiencies,
malignancies, viral infections, and psychiatric illnesses because
an improved prognosis (6, 10, 11, 13) in each of these disease
states has been associated with good NK activity.
NK cells express the leukocyte common antigen (CD45) and
some combination of CD2, CD7, CD8, CD16, CD56, and
CD57 on their surfaces (24, 30). CD2 and CD7 are present on
most T cells and NK cells, while CD8 and CD57 mark some
cytotoxic T cells and some NK cells. CD16 is an Fc receptor for
immunoglobulin G and is present on NK cells and granulo-
cytes. CD56 is found on cells of neural origin, but it is thought
to be on NK cells only in peripheral blood. NK cells also
express a number of adhesion molecules and may express ac-
tivation markers, including CD25, CD69, and HLA-DR (24,
30). While NK cells can be identified by their combination of
surface markers, there is not a unique phenotype characteristic
of all NK cells. There is conflicting evidence regarding whether
the different NK phenotypes might be representative of the
various activation states of the cells (3, 11, 12, 17, 22, 23,
27–30). Thus, at this time, it is not possible to use immuno-
phenotyping as a surrogate assay for NK cell function. Never-
theless, when NK cells are activated there are consistent
changes in the surface phenotype, primarily in the level of
expression of typical activation markers, such as the IL-2 re-
ceptor (3, 29, 30). We attempted to identify changes in phe-
notype that paralleled changes in activity by measuring the
percentage of cells expressing various NK surface markers with
and without cytokine enhancement of activity (Table 1). While
changes in the activation markers CD25 and CD69 were de-
tected, other consistent changes in specific NK phenotypes
were not clearly established. Therefore, we were unable to
identify a definite correlation between immunophenotype and
activity of NK cells. The absence of an appropriate surrogate
test further supports the use of the rapid flow cytometry-based
assay for clinical evaluations of NK cell activity.
The advantages of the flow cytometry assay are numerous. It
is less expensive than other assays, and because many clinical
immunology laboratories are already using flow cytometry for
other assays, the hardware and software for NK analysis are
currently in place. By eliminating the use of radioactivity in the
laboratory, the disposal of used supplies and old reagents
would no longer be a concern. Many laboratories not licensed
for radioisotope use would thus be able to perform the non-
radioactive assay. This assay can be effectively performed in a
few hours, similar to the more rapid 4-h chromium assay that
has also been described (4, 30). Another advantage of this
assay is that flow cytometry is being included in the proficiency
testing profile at many clinical facilities. By testing flow cytom-
etry results in an interlaboratory manner, the flow cytometric
NK assay may be suitable for standardization, which would
enhance its usefulness in the clinical laboratory. All of these
benefits of the flow cytometric assay provide reasonable justi-
fication for evaluating its usefulness.
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